What is the next treatment step for a patient who has failed etanercept (Enbrel) therapy?

Management After Etanercept (Enbrel) Failure

Switch to a different biologic agent—either another TNF inhibitor or a biologic with a different mechanism of action (IL-17 inhibitor, IL-12/23 inhibitor, or JAK inhibitor)—based on the reason for etanercept failure and patient-specific factors. 1, 2

Decision Algorithm Based on Reason for Failure

Primary Non-Response (Lack of Efficacy from the Start)

Switch to a biologic with a different mechanism of action rather than cycling to another TNF inhibitor. 1, 3

• Preferred options after primary etanercept failure:

  • IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) 1
  • IL-12/23 inhibitors (ustekinumab) 1, 4
  • JAK inhibitors (tofacitinib, upadacitinib, baricitinib) 5, 2

• The 2018 ACR/NPF guidelines conditionally recommend switching to an IL-17 inhibitor over switching to another TNF inhibitor after primary TNF failure 1

• For psoriatic arthritis specifically, IL-17 inhibitors are conditionally recommended over IL-12/23 inhibitors due to more frequent dosing requirements with the latter 1

Secondary Loss of Response (Initial Response Followed by Loss of Efficacy)

Either switch to another TNF inhibitor OR switch to a different mechanism of action—both strategies are reasonable. 2, 3

• TNF inhibitor cycling options:

  • Switch from etanercept (TNF receptor fusion protein) to a monoclonal antibody TNF inhibitor (infliximab, adalimumab, golimumab, certolizumab) 6, 2
  • Real-world data from the STURE registry showed that patients with insufficient efficacy on etanercept achieved significantly better disease control when switched to infliximab (mean DAS28 improved from 4.8 to 3.6, p<0.05) 7

• Alternative mechanism options:

  • IL-17 inhibitors, IL-12/23 inhibitors, or JAK inhibitors as listed above 1, 2

• The 2014 EULAR recommendations state that after TNF inhibitor failure, patients may receive another TNF inhibitor or a biologic with another mode of action, with no clear preference indicated 2

Intolerance or Adverse Events

Switch to another TNF inhibitor OR to a different mechanism of action, depending on the nature of the adverse event. 8, 2, 9

• For injection site reactions or mild allergic reactions:

  • Switch to a different TNF inhibitor formulation (e.g., from etanercept to a monoclonal antibody TNF inhibitor) 9, 7
  • Data from STURE registry showed patients who discontinued infliximab due to adverse events achieved similar efficacy with etanercept (mean DAS28 3.6 vs 4.1) 7

• For serious infections:

  • Consider switching to a biologic with potentially lower infection risk profile, though all biologics carry infection risk 9
  • Evaluate for underlying causes of recurrent infections before switching 9

• For class-specific adverse events (e.g., demyelinating disease, congestive heart failure, lupus-like syndrome):

  • Avoid all TNF inhibitors 1, 9
  • Switch to IL-17 inhibitor, IL-12/23 inhibitor, or JAK inhibitor 1, 5

Special Clinical Scenarios

Concomitant Inflammatory Bowel Disease (IBD)

Use a monoclonal antibody TNF inhibitor (infliximab, adalimumab, golimumab) rather than etanercept or non-TNF biologics. 1, 5

• Etanercept is not effective for IBD treatment 1, 5
• IL-17 inhibitors are contraindicated in active IBD (may worsen disease) 1, 5
• After TNF inhibitor failure in IBD patients, the 2018 ACR/NPF guidelines give a strong recommendation to switch to a monoclonal antibody TNF inhibitor over IL-17 inhibitors (moderate quality evidence) 1
• IL-12/23 inhibitors (ustekinumab) are effective for both IBD and arthritis and may be considered 5
• JAK inhibitors are effective for both conditions 5

Psoriasis with Moderate-to-Severe Skin Disease

Prioritize IL-17 inhibitors or IL-12/23 inhibitors for superior skin clearance. 4

• IL-17 inhibitors provide faster onset of action compared to IL-12/23 inhibitors 1
• IL-12/23 inhibitors offer less frequent dosing (every 12 weeks after loading) 4
• The 2009 British Association of Dermatologists guidelines list infliximab, adalimumab, ustekinumab, and etanercept as treatment options, with infliximab showing 90% clearance rates at 10 weeks 6, 4

Axial Spondyloarthritis Component

Use a monoclonal antibody TNF inhibitor or IL-17 inhibitor; avoid IL-12/23 inhibitors. 1

• IL-12/23 inhibitors have limited efficacy for axial disease 1
• Both TNF inhibitors and IL-17 inhibitors are effective for axial manifestations 1

Combination Therapy Considerations

Continue or add methotrexate when switching to the next biologic agent. 2, 10

• All biologic DMARDs demonstrate superior efficacy when combined with methotrexate compared to monotherapy 2
• The 2014 EULAR recommendations clearly prefer maintenance of combination therapy over monotherapy 2
• Exception: Tocilizumab (IL-6 inhibitor) has demonstrated efficacy as monotherapy if methotrexate is contraindicated 2

Common Pitfalls to Avoid

• Do not use etanercept in patients with active IBD—it lacks efficacy for intestinal inflammation 1, 5
• Do not use IL-17 inhibitors in patients with IBD—may exacerbate or trigger IBD 1, 5
• Do not discontinue methotrexate when switching biologics unless contraindicated—combination therapy is more effective 2
• Do not assume all TNF inhibitors are equivalent—etanercept (receptor fusion protein) has different properties than monoclonal antibody TNF inhibitors 1, 7
• Screen for latent tuberculosis and hepatitis B before initiating any new biologic agent 9

Monitoring After Switch

• Assess treatment response at 12-16 weeks for most biologics 4
• For infliximab, assess at 10-14 weeks after induction (weeks 0,2,6) 6, 4
• Continue treatment if achieving low disease activity or remission 2, 10
• If inadequate response at appropriate timepoint, switch to another agent with different mechanism of action 2